Topokine Therapeutics is a clinical-stage biotechnology company developing topical medicines that act on adipocytes to contour the face and body. The company’s lead program, XAF5 Ointment, is in Phase 2 clinical development for reduction of excess eyelid fat (steatoblepharon). Topokine’s pipeline also includes TAT4, a topical therapy that increases subcutaneous fat for rejuvenation of the hands and face.